Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

688 - Profiling of Immune related adverse events from nivolumab or pembrolizumab monotherapy in advanced non-small-cell lung cancer in real world.

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Mari Aso

Citation

Annals of Oncology (2018) 29 (suppl_9): ix150-ix169. 10.1093/annonc/mdy425

Authors

M. Aso, S. Sugawara, Y. Toi, J. Sugisaka, H. Ono, K. Tsurumi, K. Suzuki, H. Shimizu, Y. Domeki, T. Aiba, S. Kawana, R. Saito, K. Terayama, Y. Kawashima, A. Nakamura, S. Yamanda, Y. Kimura, Y. Honda

Author affiliations

  • Pulmonary Medicine, Sendai Kousei Hospital, 980-0873 - Sendai/JP
More

Resources

Abstract 688

Background

Immune checkpoint inhibitor (ICI) has now become the new standard treatment for non-small-cell lung cancer (NSCLC). However, immune-related adverse events (irAEs) are frequently observed. Little is known about the difference of profiling of irAEs between nivolumab and pembrolizumab in advanced NSCLC patients in real world.

Methods

Patients with advanced NSCLC treated with ICI at Sendai Kousei Hospital (n = 137) between January 2016 to March 2018 were included in our study. Subjects were categorized into either the patients who were treated nivolumab (Nivolumab group) or pembrolizumab (Pembrolizumab group) and were evaluated with respect to profile of irAEs, objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS).

Results

The following were observed: patient background (Nivolumab/Pembrolizumab group) number of cases 99/38 cases, median age 68/65 years old, male 79%/71%, development of irAEs 42%/63% [p = 0.047], development of irAEs ≥ Grade3 1%/21% [p> .001], Skin reaction 27%/39% [p = 0.238], Pneumonitis 7%/18% [p = 0.099], Thyroid dysfunction 13%/8% [p = 0.577], Hepatotoxicity 2%/11% [0.087]. The development of irAEs was significantly higher in the Pembrolizumab group than in the Nivolumab group (63% vs 42%, respectively; p = 0.047). The development of irAEs ≥ Grade3 was significantly higher in the Pembrolizumab group than in the Nivolumab group (1% vs 21%, respectively; p > .001). Further, in patients with PD-L1 expression 1% to 49%, we compared Nivolumab (14 cases) and Pembrolizumab group (16 cases) after second-line treatment. The development of irAEs 64%/44% [p = 0.299], development of irAEs ≥ Grade3 0%/13% [p = 0.485], ORR 21%/13% [p = 0.642], median(months) PFS 4.1/3.6 [HR (95%CI) 1.17 (0.51-2.65), p = 0.712] . No significant differences in both development of irAEs, ORR and PFS have been observed.

Conclusions

Nivolumab group might be associated with a lower incidence of severe irAEs as compared to Pembrolizumab group. However, in patients with PD-L1 expression 1% to 49% after second-line treatment, there are no significant differences in both groups. Further studies with large patient samples are needed to validate these findings.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Sendai Kosei Hospital.

Funding

Has not received any funding.

Disclosure

S. Sugawara: Ono Pharmaceutical co. Bristol-Myers Squibb MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.